CTLA4 and neoplasm: Targeting the immune checkpoint molecules programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4) leads to reinvigoration of anti-tumor immune responses in cancer patients and, consequently, improved clinical outcomes [13–16].